journal article·2018-11-05Open access

Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetration

Jialing Dai, Shangcong Han, Fang Ju, Mei Han, Lisa Xu, Ruoyu Zhang, Yong Sun

Abstract

Poor tumour penetration became a major challenge for the use of nanoparticles in anticancer therapy. To further enhance the tumour penetration efficiency, we developed a tumour-microenvironment-responsive multistage drug delivery system which was formed layer by layer via electrostatic interaction with cationic drug-loaded nanoparticles, hyaluronidase (HAase) and iRGD-modified gelatin (G-iRGD). The drug-loaded nanoparticles were formed by self-assembling mPEG-PDPA-PG and encapsulation with epirubicin (EPI). Due to the protonation of tertiary amine groups of PDPA segment in acid environment, mPEG-PDPA-PG could enhance the lysosomal escape and the intracellular release of EPI. This NPs/HAase/G-iRGD delivery system showed great biocompatibility in vitro, confirmed by MTT method. In vitro spherical tumour model penetration and in vivo tumour permeability investigation showed HAase coated NPs-EPI (NPs-EPI/HAase) could significantly enhance its penetrating efficiency. The NPs-EPI/HAase could assist in breaking down the hyaluronic acid (HA), which was a key component of extracellular matrix and thereby improving mass transport within the solid tumours. The flow cytometry studies showed that G-iRGD coated NPs-EPI (NPs-EPI/G-iRGD) was more easily taken up by HepG2 cells than gelatin coated NPs-EPI (NPs-EPI/G), which revealed the active targeting ability of iRGD. The results proved that this NPs/HAase/G-iRGD delivery system showed promising potential in enhancing tumour penetration efficiency.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China;

Department of Oncology, No. 2 Affiliated Hospital of Qingdao University, Qingdao, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province

References (44)

Show source-provided references
1. 10.18632/oncotarget.569210.18632/oncotarget.5692 ↗
2. 10.2147/IJN.S13003710.2147/IJN.S130037 ↗
3. 10.7150/thno.1174210.7150/thno.11742 ↗
4. 10.1021/bm401526d10.1021/bm401526d ↗
5. 10.1016/j.actbio.2015.12.00210.1016/j.actbio.2015.12.002 ↗
6. 10.1016/j.msec.2016.10.01810.1016/j.msec.2016.10.018 ↗
7. 10.1073/pnas.101838210810.1073/pnas.1018382108 ↗
8. 10.3109/21691401.2014.88340210.3109/21691401.2014.883402 ↗
9. 10.1016/j.msec.2017.04.09810.1016/j.msec.2017.04.098 ↗
10. 10.1016/j.msec.2017.05.05410.1016/j.msec.2017.05.054 ↗
11. 10.1016/j.msec.2017.04.11610.1016/j.msec.2017.04.116 ↗
12. 10.7150/thno.1668410.7150/thno.16684 ↗
13. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
14. 10.1021/acs.biomac.7b0006810.1021/acs.biomac.7b00068 ↗
15. 10.1016/j.biomaterials.2016.09.00110.1016/j.biomaterials.2016.09.001 ↗
16. Kandela I · ELIFE · 2017 · 6 · 110.7554/eLife.17044 ↗
17. 10.1016/j.ijpharm.2015.11.02510.1016/j.ijpharm.2015.11.025 ↗
18. 10.1016/j.biomaterials.2015.05.00610.1016/j.biomaterials.2015.05.006 ↗
19. 10.1016/j.msec.2013.12.02110.1016/j.msec.2013.12.021 ↗
20. 10.3109/21691401.2014.96274710.3109/21691401.2014.962747 ↗
21. 10.1016/j.phrs.2017.05.00410.1016/j.phrs.2017.05.004 ↗
22. 10.2174/138920021766616063020360010.2174/1389200217666160630203600 ↗
23. 10.1021/acs.molpharmaceut.7b0047510.1021/acs.molpharmaceut.7b00475 ↗
24. 10.1016/j.msec.2017.03.25910.1016/j.msec.2017.03.259 ↗
25. 10.1166/jbn.2015.214510.1166/jbn.2015.2145 ↗
26. 10.1016/j.biomaterials.2013.01.04310.1016/j.biomaterials.2013.01.043 ↗
27. 10.7150/thno.1353210.7150/thno.13532 ↗
28. 10.1016/j.biomaterials.2018.03.04610.1016/j.biomaterials.2018.03.046 ↗
29. 10.1021/acsnano.6b0507010.1021/acsnano.6b05070 ↗
30. 10.1016/j.jconrel.2018.04.00510.1016/j.jconrel.2018.04.005 ↗
31. 10.1039/C5NR01408E10.1039/C5NR01408E ↗
32. 10.1021/acs.nanolett.6b0082010.1021/acs.nanolett.6b00820 ↗
33. 10.1021/acs.nanolett.6b0006810.1021/acs.nanolett.6b00068 ↗
34. 10.1016/B978-0-12-391860-4.00006-910.1016/B978-0-12-391860-4.00006-9 ↗
35. 10.1007/978-3-319-16555-4_910.1007/978-3-319-16555-4_9 ↗
36. 10.1002/ange.20035279110.1002/ange.200352791 ↗
37. 10.1021/ja044205+10.1021/ja044205+ ↗
38. 10.1021/acs.nanolett.6b0291510.1021/acs.nanolett.6b02915 ↗
39. 10.1021/acs.biomac.7b0093110.1021/acs.biomac.7b00931 ↗
40. 10.1080/21691401.2017.130721510.1080/21691401.2017.1307215 ↗
41. 10.1016/j.biotechadv.2013.11.00910.1016/j.biotechadv.2013.11.009 ↗
42. 10.1016/j.msec.2017.03.26310.1016/j.msec.2017.03.263 ↗
43. 10.1007/s13233-012-0059-510.1007/s13233-012-0059-5 ↗
44. 10.1021/acsami.5b0939110.1021/acsami.5b09391 ↗